⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250845 | 0.87 | — | — | |
| SCHEMBL1171678 | 0.84 | — | — | |
| SCHEMBL6072128 | 0.80 | — | — | |
| SCHEMBL24679 | 0.64 | — | — | |
| SCHEMBL6555556 | 0.64 | — | — | |
| SCHEMBL1791949 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL21296705 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL21378253 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL17080536 | 0.58 | — | — | |
| SCHEMBL29941938 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005530823-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-20050215553-A1 | Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-09-29 | — | — | US | claimed |
| EP-1515953-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2005-03-23 | — | — | EP | claimed |
| WO-2003106431-A2 | NOVEL HEXAHYDRO-PYRIDAZINE-3-CARBOCYLIC ACID HYDRAZIDE OR HYDRAZONE DERIVATIVES, COMBINATORIAL LIBRARIES CONTAINING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2003-12-24 | — | — | WO | claimed |
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-118271298-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-118271297-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| CN-101031539-A | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORP (JP) | 2007-09-05 | — | — | CN | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |